The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under anesthesia.

A new study has revealed that GLP-1 drugs, commonly used for diabetes and weight loss, show promise in treating alcohol addiction. The research, published in JAMA Psychiatry, found that semaglutide and liraglutide may reduce alcohol cravings by influencing the brain's reward system.

The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require hospitalization, new research shows. Numerous studies had already hinted that semaglutide might act on appetite centers in the brain to suppress the urge to drink,

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA Psychiatry suggests.

Another day, another study linking Ozempic to major health benefits. Published Wednesday in JAMA Psychiatry, the study found that patients diagnosed with alcohol use disorder (AUD) who were given a GLP-1 drug were less likely to be hospitalized for alcohol-related issues.